Cancer drugs often don't behave as expected in clinical trials. A study published Oct. 11 in the journal Cell Chemical Biology explores why drugs under development are unlikely to work due to insufficient genetic analysis.
retrieved 25 October 2023 from https://medicalxpress.com/news/2023-10-cancer-drugs-clinical-trials.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Oct 24, 2023Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
HIF-2α inhibitor belzutifan significantly reduces progression of clear cell renal cell carcinomaBelzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.
Read more »
Revolutionary approach links protein analysis and single-cell study to uncover disease mechanismsIntegrated liquid-biopsy proteomics with single-cell transcriptomics from ocular cell types.
Read more »
Researchers identify 'switch' to activate cancer cell deathA research team from the UC Davis Comprehensive Cancer Center has identified a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can cause cells to die. This new ability to trigger programmed cell death could open the door for improved cancer treatments. The findings were published Oct.
Read more »
Researchers discover new way to trigger programmed cell death in cancer cellsA research team from the UC Davis Comprehensive Cancer Center has identified a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can cause cells to die.
Read more »
Researchers show how cancer cells resist chemotherapyA study in human cell lines reveals cancer cells can activate a force-generating mechanism to survive a cancer therapy.
Read more »
Study shows skin cancer diagnoses using AI are as reliable as those made by medical expertsArtificial intelligence (AI) is already widely used in medical diagnostics. An Austrian-Australian research team led by dermatologist Harald Kittler from MedUni Vienna has investigated the extent to which diagnosis and therapy of pigmented skin lesions benefit from it in a realistic clinical scenario.
Read more »